NasdaqCM - Nasdaq Real Time Price USD

Entero Therapeutics, Inc. (ENTO)

0.4180

+0.0140

+(3.47%)

At close: May 14 at 4:00:02 PM EDT

0.4179

-0.00

(-0.02%)

After hours: May 14 at 5:28:09 PM EDT

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business C

Newsfile last month

ENTO
+3.47%
Entero Therapeutics Appoints Richard Paolone as CEO

BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, a

GlobeNewswire 2 months ago

ENTO
+3.47%
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has secured a $2 million revolving loan agreement and subsequently appointed three new members to its Board of Directors. As a condition for the loan, Entero replaced three of five members of its Board of Di

GlobeNewswire 3 months ago

ENTO
+3.47%
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of Entero Therapeutics, will moderate the "CEO Insights: Lessons Learned & Strategies for Driving Innovation," CEO Forum which will be held on Tuesday, November

GlobeNewswire 5 months ago

ENTO
+3.47%
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases;The NIC platform technology is invented by and originated from Svetomir N. Markovic, M.D., Ph.D. of Mayo Clinic

GlobeNewswire 5 months ago

ENTO
+3.47%
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial complianceBOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced its entry into a bindi

GlobeNewswire 7 months ago

ENTO
+3.47%
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q fo

GlobeNewswire 8 months ago

ENTO
+3.47%
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company’s Chairman and CEO, to provide stockholders with a business update. LETTER FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER To my fellow stockholders, We are ma

GlobeNewswire 9 months ago

ENTO
+3.47%
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 pe

GlobeNewswire 9 months ago

ENTO
+3.47%
Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Oral presentation will showcase novel VCIEL scale for assessing small intestinal mucosal health in Celiac DiseaseBOCA RATON, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that an abstract has been accepted for oral presentation at the 20th International Celi

GlobeNewswire 9 months ago

ENTO
+3.47%
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the potential importance of VCIEL for CeD research and clinical trials BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapi

GlobeNewswire 10 months ago

ENTO
+3.47%
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Late clinical-stage company to provide update on Phase 3 treatment for celiac diseaseBOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 20

GlobeNewswire 11 months ago

ENTO
+3.47%
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trialsBOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at

GlobeNewswire 11 months ago

ENTO
+3.47%

Performance Overview

Return	ENTO	S&P 500 (^GSPC)
YTD	-32.80%	+0.19%
1-Year	-85.93%	+12.31%
3-Year	-99.97%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Entero Therapeutics, Inc. (ENTO)

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Entero Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Performance Overview